From Risk-Based Monitoring to Risk-Based Validation

From Risk-Based Monitoring to Risk-Based Validation

Prioritizing Resources for System Validation and Data Integrity in Life Sciences

February 19, 2025

In 2012, clinical operations teams faced a stark reality: 30% of trial budgets were routinely consumed by site monitoring. It was demonstrated that a prime on-site activity, Source Document Verification (SDV), yielded minimal improvements in data quality. Clinical Data Managers (CDMs) bore the burden of ensuring data integrity, while Clinical Research Associates (CRAs) spent countless hours in transit and on-site manually verifying data listings. The revelation that SDV contributed minimally to data accuracy while consuming substantial resources sparked a transformative shift—Risk-Based Monitoring (RBM). With FDA endorsement, organizations learned to focus monitoring efforts where they mattered most, prioritizing critical data and high-risk sites rather than verifying every data point equally.

Today, validation teams face a similar challenge. In today’s climate, the economic implications are stark. It is not feasible to maintain the bookshelves full of binders overflowing with documentation: exhaustive test scripts, screenshots, handwritten notes, and ink signatures, representing the expenditure of vast resources while adding questionable value to patient safety and data quality. Nor is it necessary. Technology advances and re-evaluation of the effectiveness of traditional validation methods have led to new approaches.

The clinical research industry solved its resource problem through RBM. Validation is now at a similar inflection point, where risk-based methodologies that leverage new technology can ensure that resources are prioritized effectively, focusing efforts on what matters most.

CSV and CSA: A Continuum, Not a Replacement

Computer System Validation (CSV) has provided the foundation for GxP software assurance for decades, guided by key standards such as FDA’s 21 CFR Part 11, the EU Annex 11 guidelines, and the ISPE GAMP® 5 framework. CSV introduced rigor into software development, ensuring the start of the CSV process—building and installing the system—was handled with precision and consistency. This allowed systems to be validated, proving they were demonstrably fit for their intended use through thorough documentation and testing.

However, the industry’s reliance on exhaustive documentation often led to misplaced emphasis and inefficient use of resources. Recognizing this, the FDA introduced Computer Software Assurance (CSA) in 2022, not as a replacement for CSV but as an enhancement that leverages risk-based approaches and critical thinking. CSA allows validation teams to apply proportional validation efforts without sacrificing compliance or quality. Importantly, CSA does not supersede CSV but serves as an adjunct framework, encouraging critical thinking in determining which system elements require the most rigorous validation efforts.

This shift parallels the RBM evolution, where risk assessments drove monitoring priorities. CSA’s risk-based approach enables validation teams to apply different levels of assurance based on feature risk, thus maintaining robust compliance while optimizing resource use.

Just as RBM taught us to differentiate monitoring based on site risk and critical data points, CSA allows us to calibrate validation efforts based on feature complexity, data point criticality, and quality risk. For example, critical calculations affecting patient dosing require extensive testing, while basic demographic data entry screens can utilize streamlined approaches.

This evolution aligns closely with GAMP® 5’s risk-based approach, emphasizing the importance of critical thinking and proportional validation efforts. By leveraging established CSV principles and enhancing them through CSA, organizations can ensure that validation remains both compliant and efficient in a rapidly evolving technological landscape.

The approach can be leveraged throughout the system’s maintenance lifecycle. System modules whose functionality has been tested rigorously in previous releases can be verified with minimal testing in a patch or upgrade release, as long as the regression risk, based on its interconnectedness with other new or updated modules, is deemed to be low.

The parallels between the move to RBM and CSA are striking. Both transformations acknowledge a fundamental truth: with finite resources, organizations must focus efforts where they matter most. Risk becomes the common thread, providing a framework for making these decisions systematically rather than arbitrarily.

Enhancing RBM

RBM’s success laid the foundation for Risk-Based Quality Management (RBQM), where Key Risk Indicators (KRIs) help organizations monitor and manage critical quality attributes throughout the clinical trial lifecycle. KRIs serve as early warning signals, focusing resources and enabling proactive risk mitigation. This concept of using KRIs to dynamically manage quality resonates with CSA’s approach to continuously assess and mitigate risks in software validation processes.

Modern technology is enabling this evolution. Just as RBM leveraged central statistical monitoring, risk-based validation is supported by advanced digital tools that enable real-time risk assessment, seamless documentation, and dynamic test management. These platforms not only streamline validation efforts but also provide continuous visibility into system risk, ensuring that critical quality attributes are maintained without unnecessary overhead.

In future articles, we’ll explore specific aspects of this transformation—from practical CSA implementation to the broader role of Risk-Based Quality Management (RBQM) maybe able to incorporate validation in the umbrella of ensuring data integrity, product quality, and regulatory compliance. We’ll examine how risk-based validation aligns with comprehensive quality management strategies, much like RBM evolved into RBQM.

Ready to learn more? Stay tuned for our upcoming articles, where we’ll dive deeper into how KRIs and RBQM can reshape validation strategies. If you’re exploring risk-based validation for your organization, let’s connect to discuss your journey and how to optimize your validation approach.

[Contact Driftpin](http://Contact Driftpin Consulting)

Mini Reading List: Essential References for Risk-Based Validation

1. FDA, General Principles of Software Validation (2002)

This foundational guidance provides the core principles of Computer System Validation (CSV), establishing regulatory expectations for software used in regulated life sciences settings.
📄 Read here

2. FDA, Computer Software Assurance (CSA) Draft Guidance (2022)

CSA builds upon CSV, emphasizing risk-based approaches to validation, allowing companies to focus efforts on high-risk system elements rather than exhaustive documentation.
📄 Read here

3. ISPE GAMP® 5: A Risk-Based Approach to Compliant GxP Computerized Systems (2nd Edition, 2022)

GAMP 5 provides a structured approach to CSV, integrating risk-based methodologies that align closely with the principles of CSA.
📄 Read here

4. EU Annex 11: Computerized Systems (2011)

Annex 11 outlines the EU’s expectations for the use of computerized systems in regulated environments, emphasizing data integrity, system security, and risk-based validation practices.
📄 Read here

5. ICH E6(R2): Good Clinical Practice (GCP) Guidelines

ICH E6(R2) formalized the risk-based approach to monitoring (RBM), which parallels how CSA applies risk-based thinking to validation efforts.
📄 Read here

6. EU GMP Chapter 4: Documentation

This chapter provides guidance on Good Manufacturing Practice (GMP) documentation standards, essential for maintaining data integrity and traceability in validation processes.
Read here

7. TransCelerate BioPharma: Risk-Based Monitoring Methodology (RBM) Framework

This industry-developed framework introduced KRIs and risk-based monitoring concepts, which now serve as a foundation for Risk-Based Quality Management (RBQM) strategies.
Read here